Search hospitals > Nebraska > Lincoln
Nebraska Hematology and Oncology
Claim this profileLincoln, Nebraska 68506
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
99 reported clinical trials
3 medical researchers
Summary
Nebraska Hematology and Oncology is a medical facility located in Lincoln, Nebraska. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Nebraska Hematology and Oncology is involved with conducting 99 clinical trials across 142 conditions. There are 3 research doctors associated with this hospital, such as Ralph Hauke, MD, Kailash Mosalpuria, and Irfan Vaziri.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage I
Stage II
2Cancer
Global LeaderStage I
Stage II
Stage IV
Top PIs
Ralph Hauke, MDNebraska Cancer Specialists5 years of reported clinical research
Expert in Cancer
Studies Prostate Cancer
35 reported clinical trials
73 drugs studied
Kailash MosalpuriaNebraska Hematology-Oncology, P.C.1 year of reported clinical research
Studies Breast Cancer
Studies Lung Cancer
5 reported clinical trials
12 drugs studied
Irfan VaziriNebraska Hematology - Oncology, P.C.2 years of reported clinical research
Studies Plasma Cell Neoplasms
Studies Multiple Myeloma
1 reported clinical trial
4 drugs studied
Clinical Trials running at Nebraska Hematology and Oncology
Non-Small Cell Lung Cancer
Lung Cancer
Laryngeal Cancer
Oropharyngeal Carcinoma
Cancer
ALK Gene Rearrangement
Breast Cancer
Squamous Cell Carcinoma
Oral Cavity Carcinoma
Hypopharyngeal Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Telisotuzumab Vedotin vs. Docetaxel
for Non-Small Cell Lung Cancer
This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
Recruiting2 awards Phase 312 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Nebraska Hematology and Oncology?
Nebraska Hematology and Oncology is a medical facility located in Lincoln, Nebraska. This center is recognized for care of Lung Cancer, Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Nebraska Hematology and Oncology is involved with conducting 99 clinical trials across 142 conditions. There are 3 research doctors associated with this hospital, such as Ralph Hauke, MD, Kailash Mosalpuria, and Irfan Vaziri.